• 1
    Kantarjian H, O'Brien S, Anderlini P, et al. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood. 1996; 87: 3069.
  • 2
    Faderl S, Talpaz M, Estrov Z, et al. Chronic myelogenous leukemia: update on biology and treatment. Ann Intern Med. 1999; 131(3): 207219.
  • 3
    Guilhot F, Chastang C, Michallet M, et al. Interferon-alpha 2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997; 337: 223.
  • 4
    Tura S. Cytarabine increases karyotypic response in alpha-IFN treated chronic myeloid leukemia patients: results of a national prospective randomized trial. Blood. 1998; 92: 317.
  • 5
    Kantarjian HM, O'Brien S, Smith T, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon-alpha and low dose cytosine arabinoside. J Clin Oncol. 1999; 17: 284292.
  • 6
    The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994; 330: 820825.
  • 7
    Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomized, multicenter trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukemia. Lancet. 1995;345: 13921397.
  • 8
    Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst. 1997; 89: 16161620.
  • 9
    Cephalotaxus Research Coordinating Group. Cephalotaxine esters in the treatment of acute leukemia: a preliminary clinical assessment. Chinese Med J. 1976; 2(2): 263272.
  • 10
    Chinese People's Liberation Army 18th Hospital. On the treatment of leukemias: clinical analysis of 72 cases. Zhonghua Yizue Zazhi. 1978; 58(3): 163.
  • 11
    Warrell RP, Coonley CJ, Gee TS. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. J Clin Oncol. 1985; 3(5): 617621.
  • 12
    Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia. 1992; 6(11): 11851188.
  • 13
    Feldman EJ, Seiter KP, Ahmed T, et al. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia. 1996; 10(1): 4042.
  • 14
    Kantarjian H, Keating M, McCredie K, et al. Phase II study of homoharringtonine in refractory acute myelogenous leukemia. Cancer. 1989; 63: 813817.
  • 15
    O'Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995; 86(9): 33223326.
  • 16
    Visani G, Russo D, Ottaviani E, et al. Effect of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on “in vitro” growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia. 1997; 11: 624628.
  • 17
    O'Brien S, Kantarjian H, Koller C, et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood. 1999; 93(12): 41494153.
  • 18
    Kantarjian HM, Talpaz M, Smith TL, et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2000; 18(20): 35133521.
  • 19
    National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda: Division of Cancer Treatment, National Cancer Institute, 1988.
  • 20
    Kantarjian HM, Giles FJ, O'Brien S, et al. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am. 1998; 12: 3180.
  • 21
    Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med. 1995; 122: 254261.
  • 22
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 58: 457481.
  • 23
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc. 1972; 34: 187220.
  • 24
    Kantarjian HM, Smith TL, McCredie KB, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood. 1985; 66: 1326.
  • 25
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med. 2001; 344(14): 10311037.